Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Seres Therapeutics
Biotech
Seres slims R&D, staff to focus on approved microbiome drug
After securing an approval for a microbiome therapy, Seres is facing some tough choices, resulting in a restructuring that will claim 41% of staff.
Annalee Armstrong
Nov 2, 2023 12:22pm
Leaps by Bayer chief jumps to Bayer, too—Chutes & Ladders
Aug 25, 2023 9:30am
FDA mulls approving first oral microbiome therapy from Seres
Oct 26, 2022 9:55am
Equipped with new safety data, Seres eyes FDA approval
Jun 7, 2022 7:00am
Seres Therapeutics' microbiome therapy flops against placebo
Jul 22, 2021 7:30am
Nestlé, Seres re-up microbiome partnership in $175M deal
Jul 1, 2021 12:00pm